Remeron Articles
Pfizer debuts generic drug portfolio in the UK
3 February 2010
Lexapro and Zoloft are "best" antidepressants
9 February 2009
Schering-Plough finally back in profit after Organon buy; exceeds expectations, pleasing shareholders
9 February 2009
ACP guidelines recommend 2nd-generation antidepressants
24 November 2008
Nippon Organon submits mirtazapine
22 January 2007
Akzo's income hits 313M euro for 3rd-qtr
23 October 2006
Akzo Nobel's 2nd-qtr sales hit 3.57B euros
31 July 2006
Akzo 2005 income rises 1.7%, Organon gains
13 February 2006
Par receives go-ahead for mirtazapine ODT
12 September 2005
US FDA posts DSOB meeting summary
15 August 2005
FDA OKs Teva's generic mirtazapine
11 July 2005
EMEA warning over SSRIs, SNRIs in children
26 April 2005
1st-qtr net doubles for Akzo Nobel
25 April 2005
Akzo Nobel's 4th-qtr and 2004 sales down
14 February 2005
Akzo Nobel does not rule out pharma sale
22 November 2004
Akzo settles further Remeron law suits
11 October 2004
Meiji obtains rights to mirtazapine in Japan
16 August 2004
Akzo's 2nd-qtr pharma sales slip further
26 July 2004
Stock Commentary - Europe
5 July 2004
Organon's gepirone rejected in the USA
5 July 2004
Par Pharma buys Kali Labs in $135M deal
21 June 2004
Tough times ahead for pharma at Akzo Nobel
26 April 2004
Akzo Nobel settles US Remeron cases
26 April 2004
Green light for 150mg Wellbutrin generics
29 March 2004
Akzo Nobel's pharma sales drop further
9 February 2004
Akzo Nobel pharma under pressure
27 October 2003
Pfizer and Organon enter collaboration
27 October 2003
Organon launches Zispin SolTab in UK
13 October 2003
Akzo pharma unit struggles in 2nd qtr
28 July 2003
FDA approves several generic forms of Remeron
30 June 2003
Akzo Nobel 1st qtr earnings plunge 30%
28 April 2003
Akzo Nobel pharma unit
17 February 2003
Akzo Nobel predicts a difficult 2003
13 January 2003
Barr Labs being sued by Organon, Shire
13 May 2002
Akzo set to break record level profits
29 April 2002
Mylan gets OK for generic Remeron in USA
4 February 2002
Teva gets initial OK for generic mirtazepine.
21 January 2002
Akzo Nobel predicts double-digit pharma growth for 2001
10 October 2001
Strong performance in 2000 for Akzo Nobel as pharma drives growth
26 February 2001
Akzo, Solvay combine to push Remeron SolTab in USA
8 February 2001
US appro on Organon's Remeron SolTab
15 January 2001
Pharmaceutical sales continue to drive growth at Akzo Nobel
25 October 2000
Pharma sales up 39% at Akzo Nobel
28 July 2000
Akzo Nobel net income jumps 30%
26 April 2000
Akzo Nobel to rely on organic growth in niche markets
28 February 2000
Akzo results driven by pharma growth
27 October 1999
Akzo Nobel posts solid results for second qtr
29 July 1999
Healthy pharma sales for Akzo Nobel
23 April 1999
Pharmaceuticals "star performer" for Akzo
23 February 1999
Akzo Nobel Expands Scottish R&D Unit
15 December 1998
Akzo Nobel Pharma Sales Slowdown
30 October 1998
Akzo Nobel Reports Disappointing 2nd Qtr
30 July 1998
Remeron Outperforms SSRIs In Trials
22 July 1998
Akzo Nobel Looking To US Growth
16 June 1998
Net Income Up 21% At Akzo Nobel
24 April 1998
Buoyant Results For Akzo Nobel, Says Broker
3 March 1998
High 3rd Qtr Net Income For Akzo
4 November 1997
Good 2nd Qtr Pharma Performance At Akzo Nobel
7 August 1997
Pharma Flat At Akzo Nobel In 3rd Qtr
11 November 1996
EUROPEAN STOCK COMMENT
7 October 1996
Organon's Remeron
30 September 1996
Organon's Remeron Is "Better Than Prozac"
30 September 1996
Akzo Nobel Sees Earnings Decline
19 August 1996
Organon's Remeron Cleared In USA
24 June 1996
Mirtazepine Nears US Approval; 1st Alpha2 Blocker Antidepressant
30 October 1995
New Chemical Entities Round-Up For 1994
6 February 1995
European Stock Comment
9 January 1995
B-MS' Nefazodone: Launch Soon In USA
9 January 1995
First Launch For Organon's Mirtazapine
2 January 1995
Showing 1-86 of 86 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
